/

KTTA

Pasithea Therapeutics Corp.Closed

0.4238−0.02 −5.30%USD

NasdaqCM · as of Oct 13, 16:00 ET · 15m delayAfter hours 0.4234 −0.09%

Open

0.4500

Prev close

0.4475

Day range

0.41000.4500

52-week range

0.28102.06

Volume

60.05K0.27×

Mkt cap

14.16M

P/E ttm

—

Fwd P/E

-0.92

EPS ttm

-1.59

Div yield

0.00%

Earnings

—

From 52w high

−79.43%

Price Chart

Yahoo Finance · delayed

KTTAOct 13, 2026O 0.4500H 0.4500L 0.4100C 0.4240−0.0240 (−5.36%)Vol 60.10K

SMA 500.5047
SMA 2000.6732

1Y change −43.39% since Oct 10, 2025 close539 bars loadedTimes in America/New_YorkDraw from the left toolbar · click a drawing to edit · right-click for alerts and export

KTTA Pasithea Therapeutics Corp. · Last Guard Finance

DES

Key Statistics

Yahoo Finance

Performance

1 week: −5.15%
1 month: −20.00%
3 months: −12.03%
6 months: −46.33%
Year to date: −67.13%
1 year: −43.01%

Valuation & ownership

Market cap: 14.16M
Enterprise value: −31.50M
P/E (ttm): —
Forward P/E: -0.92
PEG ratio: —
Price / book: 0.28
Price / sales (ttm): —
EV / EBITDA: 1.65
EPS (ttm): -1.59
EPS (forward): -0.4600
Beta (5y monthly): 0.34
Dividend yield: 0.00%
Payout ratio: —
Shares outstanding: 33.41M
Float: 19.68M
Short % of float: 0.48%
Short ratio (days): 0.83
Held by insiders: 1.11%
Held by institutions: 63.23%
Avg volume (3m): 219.64K
50-day average: 0.5052
200-day average: 0.6769
52-week change: −43.01%
S&P 500 52-week: +17.03%

Technicals (daily)

RSI (14): 33.1
vs 50-day SMA: −16.00%
vs 200-day SMA: −37.02%
50 / 200-day trend: ▼ 50 below 200
MACD vs signal: ▼ below
ATR (14) % of price: 8.02%
Realised vol (20d, ann.): 47.0%
From 52-week high: −79.42%
From 52-week low: +50.89%

ANR

Analyst Consensus

1 analysts

Consensus

—

Mean target

3.00

+607.88% implied

Low 3.00Median 3.00High 3.00

Recommendation trend

Now1 / 0 / 0
1m ago1 / 0 / 0

Buy / hold / sell counts

DES

About Pasithea Therapeutics Corp.

Yahoo Finance profile

Pasithea Therapeutics Corp., a clinical-stage biotechnology company, focuses on the discovery, research, and development of treatments for central nervous system (CNS) disorders, RASopathies, and cancers. Its lead product candidate is PAS-004, a next-generation macrocyclic mitogen-activated protein kinase, or MEK inhibitor to treat a range of RASopathies, including neurofibromatosis type 1 (NF1); MAPK pathway-driven tumors, such as BRAFv600 and BRAF fusion tumor; and ETS2 driven diseases, including inflammatory bowel disease (IBD), primary sclerosing cholangitis, and ankylosing spondylitis. The company's lead development candidate is PAS-003, to treat amyotrophic lateral sclerosis. It also intends to develop PAS-001, to treat schizophrenia. Pasithea Therapeutics Corp. was incorporated in 2020 and is headquartered in Miami Beach, Florida.

Sector: Healthcare
Industry: Biotechnology
Employees: 5
Headquarters: Miami Beach, FL, United States
Website: pasithea.com
Officers: Dr. Lawrence Steinman BA, M.D., Ph.D. Co-Founder & Executive Chairman
Dr. Tiago Reis Marques M.D., Ph.D. CEO & Director
Mr. Daniel H. Schneiderman Chief Financial Officer
Dr. Kartik Krishnan M.D., Ph.D.

SEAS

Seasonality · KTTA

2021–2026 · monthly returns

Strongest month Nov +14.71%Weakest month May −22.79%Averages use completed years only. Past seasonality doesn't predict future returns.

Year	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec	Year
2026	-33.3	2.4	-15.9	-6.3	2.9	-28.0	-10.7	24.8	-14.1	-14.0			−67.1%
2025	-28.9	-48.2	12.1	27.7	-41.6	-25.7	0.6	11.4	-9.4	11.2	80.6	-12.2	−59.0%
2024	-11.5	22.1	-9.4	-4.6	-21.1	-7.3	3.7	-13.3	19.1	-30.0	-18.6	1.9	−57.4%
2023	9.5	-31.7	-21.9	-6.7	0.0	40.0	22.0	1.3	-20.8	-27.1	-6.9	13.5	−42.4%
2022	-27.1	-20.9	27.5	-7.7	-28.5	17.7	14.9	-0.9	9.6	-13.5	-9.2	-35.2	−63.7%
2021										-6.9	27.6	-51.0	−41.8%

INSD

Insider Activity · KTTA

Market-wide insider buying →Congress trades →SEC Form 4 filings via Yahoo Finance

Buys, 6 months

0 shares

Sells, 6 months

— shares

Net shares

Net change in insider shares

—

Date	Insider	Transaction	Shares	Value
Jun 16, 2026	Coastlands Capital LpBeneficial Owner of more than 10% of a Class of Security	Purchase at price 0.53 per share.	100K	$53.00K
Nov 27, 2025	Schneiderman Daniel HChief Financial Officer	Stock Award(Grant) at price 1.47 per share.	26.7K	$39.20K
Nov 27, 2025	Leahy EmerDirector	Stock Award(Grant) at price 1.47 per share.	33.3K	$49.00K
Nov 27, 2025	Steinman LawrenceDirector	Purchase at price 1.47 per share.	133.3K	$196.00K
Nov 27, 2025	Marques Tiago ReisChief Executive Officer	Purchase at price 1.47 per share.	33.3K	$49.00K
Nov 27, 2025	Dumesnil SimonDirector	Purchase at price 1.47 per share.	33.3K	$49.00K
May 11, 2025	Marques Tiago ReisChief Executive Officer	Sale at price 0.82 per share.	960	$792

13F

Investors Holding KTTA

latest 13F filings of 29 followed managers

Investors holding KTTA
Investor	Value	Of portfolio	Shares	Change	Quarter
Renaissance Technologies	$33.8K	0.00%	65.60K	−30%	Q2 2026

From each investor's quarterly 13F filing with the SEC: positions at the quarter's end, reported up to 45 days later. All investors

KTTA

Price Chart

Keyboard shortcuts & functions

Anywhere

Command line

Charts (click the chart first)

Function codes

KTTA

Price Chart

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Pasithea Therapeutics Corp.

Seasonality · KTTA

Insider Activity · KTTA

Congress Trades · KTTA

Investors Holding KTTA

Investors Holding KTTA

Congress Trades · KTTA

Insider Activity · KTTA

Seasonality · KTTA

Key Statistics

Performance

Valuation & ownership

Technicals (daily)

Analyst Consensus

About Pasithea Therapeutics Corp.

Financial Snapshot

Earnings & Dividends

News